Incyte (INCY) Total Non-Current Liabilities (2013 - 2026)
Incyte posted quarterly Total Non-Current Liabilities of $1.6 billion for Q1 2026, down 16.61% year-on-year from $1.9 billion in Q1 2025, and down 2.19% on a QoQ basis from $1.6 billion in Q4 2025.
Incyte (INCY) has 14 years of Total Non-Current Liabilities data on file, last reported at $1.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 16.61% year-over-year to $1.6 billion; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (down 16.61% YoY), and the FY2025 full-year result was $1.6 billion, down 11.15% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $1.6 billion, down from $1.6 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.9 billion in Q1 2025 and bottomed at $1.1 billion in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $1.5 billion (2025), against an average of $1.5 billion.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities surged 54.44%; it then slipped 16.61% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $1.3 billion in 2022, then rose by 12.18% to $1.4 billion in 2023, then grew by 26.75% to $1.8 billion in 2024, then slipped by 11.15% to $1.6 billion in 2025, then decreased by 2.19% to $1.6 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 1.59 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.59 Bn |
| Dec 31, 2025 | 1.63 Bn |
| Sep 30, 2025 | 1.51 Bn |
| Jun 30, 2025 | 1.47 Bn |
| Mar 31, 2025 | 1.91 Bn |
| Dec 31, 2024 | 1.83 Bn |
| Sep 30, 2024 | 1.70 Bn |
| Jun 30, 2024 | 1.52 Bn |
| Mar 31, 2024 | 1.58 Bn |
| Dec 31, 2023 | 1.44 Bn |
| Sep 30, 2023 | 1.32 Bn |
| Jun 30, 2023 | 1.29 Bn |
| Mar 31, 2023 | 1.22 Bn |
| Dec 31, 2022 | 1.29 Bn |
| Sep 30, 2022 | 1.11 Bn |
| Jun 30, 2022 | 1.16 Bn |
| Mar 31, 2022 | 1.12 Bn |
| Dec 31, 2021 | 1.09 Bn |
| Sep 30, 2021 | 987.87 Mn |
| Jun 30, 2021 | 749.75 Mn |
| Mar 31, 2021 | 879.13 Mn |
| Dec 31, 2020 | 722.05 Mn |
| Sep 30, 2020 | 683.65 Mn |
| Jun 30, 2020 | 631.23 Mn |
| Mar 31, 2020 | 574.84 Mn |
| Dec 31, 2019 | 585.39 Mn |
| Sep 30, 2019 | 219.80 Mn |
| Jun 30, 2019 | 450.37 Mn |
| Mar 31, 2019 | 415.83 Mn |
| Dec 31, 2018 | 203.00 Mn |
| Sep 30, 2018 | 203.70 Mn |
| Jun 30, 2018 | 405.74 Mn |
| Mar 31, 2018 | 656.71 Mn |
| Dec 31, 2017 | 157.80 Mn |
| Sep 30, 2017 | 356.88 Mn |
| Jun 30, 2017 | 599.81 Mn |
| Mar 31, 2017 | 628.79 Mn |
| Dec 31, 2016 | 1.21 Bn |
| Sep 30, 2016 | 161.00 Mn |
| Jun 30, 2016 | 844.60 Mn |
| Mar 31, 2016 | 827.96 Mn |
| Dec 31, 2015 | 787.90 Mn |
| Sep 30, 2015 | 137.30 Mn |
| Jun 30, 2015 | 823.31 Mn |
| Mar 31, 2015 | 851.13 Mn |
| Dec 31, 2014 | 823.55 Mn |
| Sep 30, 2014 | 822.47 Mn |
| Jun 30, 2014 | 805.70 Mn |
| Mar 31, 2014 | 795.21 Mn |
| Dec 31, 2013 | 795.87 Mn |
| Sep 30, 2013 | 325.22 Mn |
| Jun 30, 2013 | 358.57 Mn |